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The International Conference on Typhoid Fever and 
Other Salmonelloses is organized every two to three 
years and has usually taken place in Asia. The first 
meeting was held in Malaysia 15 years ago. The 6th 
international meeting, held in Guilin, China, in Novem-
ber 2005, was organized by the Guangxi Centre for Dis-
ease Prevention and Control, in collaboration with the 
World Health Organization (WHO), the International 
Vaccine Institute (IVI), and the American Society for 
Microbiology (ASM). Two hundred fifty participants 
from 27 countries, including Africa, participated.   
  Nine sessions covering the major topics of interest 
provided the latest updated information on typhoid fe-
ver. These include: Epidemiology and disease burden; 
Molecular pathogenesis and genomics; Contemporary 
issues in vaccine development; Diagnostics in typhoid 
fever; Antimicrobial resistance in typhoid fever; Clini-
cal and therapeutic aspects; Socio-behavioural research; 
Other salmonelloses-related contemporary issues; and a 
Roundtable on Expanding Vaccine Implementation in 
Developing Countries.
  Travel grants for participants from developing coun-
tries were supported by the WHO, IVI, and the ASM, 
and by the Conference Organizing Committee.
Epidemiology and disease burden
During the epidemiology session, general consensus 
was raised that typhoid fever remains an important, but 
under-estimated, disease which has high mortality in de-
veloping countries, particularly in Asia. However, there 
are extremely limited data from Africa, and the burden 
of disease is probably under-estimated in this region. 
Endemic disease in South-East Asia is observed to be 
high, although it varies greatly in different settings. In 
addition, disease in the paediatric population was higher 
than previously recognized.
  The latest published figure for the estimated number 
of cases is approximately 22 million per year, with an 
estimated 210,000 deaths (1). This number of deaths 
was calculated from a conservative figure using a case-
fatality rate (CFR) of 1%. However, the reported CFR 
from presentations during the meeting was generally 
much higher than this in different studies, with the gen-
eral agreement that this 1% estimate was under-esti-
mated and that additional robust studies are required. 
It was suggested that WHO should convene a consulta-
tive meeting to resolve this during 2006. Second, the 
increasing number of Salmonella Paratyphi A isolates 
recovered in Asia, particularly in China and Pakistan, 
was noted with concern. In Guingxi province of China, 
94% of Salmonella isolates are currently S. Paratyphi 
A. This situation raised the point of accelerating the 
development of S. Paratyphi A vaccine candidates. 
Molecular pathogenesis and genomics
Developments in molecular pathogenesis and genomics 
highlighted the difficulties that surround the serotyping 
of Salmonella species and the classification of Salmo-
nella strains. The full genome sequence of Salmonella 
strains indicates that the S. Typhi and S. Paratyphi A have 
a recent evolutionary history. Using this sequence data, 
a novel system based on multi-locus sequences typing 
(MLST) has been devised which should help type Sal-
monella strains in a more precise approach and could re-
place classical serotyping in future. New data from Viet 
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associated with fever-clearance time in patients. Indi-
viduals who have the protective haplotype (*12*22**1) 
cleared their fever significantly faster than individuals 
who did not have this haplotype. Better understanding 
of the organization of Salmonella pathogenicity islands 
and diversity of Typhi flagellar antigen expression were 
presented. Finally, it was recommended that further re-
search was required on (a) S. Typhimurium in Africa, 
(b) paediatric versus adult strains of S. Typhi, and (c) 
molecular epidemiology of outbreaks versus endemic 
strains.
Contemporary issues in vaccine development
Besides the currently-licensed and available vaccines 
(Vi polyssacharide and Ty21a), other candidate vaccines, 
consisting of either subunit vaccine or live-attenuated 
vaccines, were described. The Vi polysacharide vaccine 
is now locally produced in several developing coun-
tries, such as China, Viet Nam, and Cuba. This vaccine, 
extensively evaluated in Asia, through the DOMI 
programme of IVI, Seoul, demonstrated a confirmed 
protective efficacy of more than 70% when used in one 
injection, either in prevention in endemic areas or dur-
ing an outbreak of typhoid fever. This sugar-based vac-
cine does not confer long-lasting immunogenicity in 
infants aged less than two years, and therefore, a conju-
gate vaccine was deve-loped by National Institutes of 
Health (NIH), USA, and evaluated in young children. A 
phase III efficacy study in Vietnamese children, aged 
2-5 years, demonstrated a protective efficacy of 91% 
after 27 months of active surveillance. Passive surveil-
lance for another 16 months (3½ years of total follow-
up) showed 82% protection against the infection. 
Evaluation of the Vi conjugate vaccine has also been 
conducted in infants aged 9-17 months. A live-atten-
uated oral dose candidate vaccine (Ty800), evaluated 
in in-patients, showed that a single, oral dose was well-
tolerated and immunogenic over a wide dose range, and 
no subjects showed any signs of vaccine bacteraemia. 
Phase I/II studies are planned.  
  Another live-attenuated single oral dose candidate 
(CVD 909 developed by the Center for Vaccine De-
velopment, Baltimore), which produces both Vi and O 
antibody responses in a murine model, is under evalu-
ation. In Mexico, a S. Typhi OMP (outer-membrane 
protein)-based approach was discussed showing that 
the OMPc produced a long-lasting immune response in 
mice >300 days. Induction of specific bactericidal anti-
body and cellular immune response was also reported in 
healthy volunteers. Because of the increasing number 
of S. Paratyphi A isolates, research is also focusing on 
the development of vaccine against infection due to this 
organism. Therefore, two approaches—live and con-
jugate vaccine development—were taken. A live-at-
tenuated anti-typhoid/paratyphoid A and B single oral 
dose vaccine is under development in Switzerland. The 
vaccine strains were generated by a non-recombinant 
technology. A S. Paratyphi A conjugate vaccine, devel-
oped in China, in collaboration with NIH, was evaluated 
successfully in animals, and there are plans for its clini-
cal evaluation. Food and Drug Administration (FDA)/
Center for Biologics Evaluation and Research (CBER), 
USA, is using Ty21a as a live-attenuated vector for de-
veloping a multi-valent vaccine that has the potential to 
provide protection against typhoid fever and shigello-
sis. 
Diagnostics in typhoid fever   
Discussions concerning the ongoing problems with di-
agnosis of typhoid fever and the development of new 
assays were raised. The clinical diagnosis of typhoid 
fever could be confused with other long-lasting fevers, 
and therefore, it was important to have a reliable and 
early diagnostic assay for this infection. Blood culture 
remains the definitive assay, but is known to miss cases 
by as much as 50%. The currently-available rapid tests 
(Typhidot and Tubex), evaluated in Asia, Pakistan, 
Bangladesh, and the Philippines, showed improved 
diagnostic reliability. New-generation tests, such as 
Dipstick-IgM and Typhi-rapid tests, have been devel-
oped for the early detection of IgM antibodies. These 
new-generation tests are very rapid taking from 10 to 
15 minutes per test and for at least one manufacturer 
advances allow the testing of haemolyzed blood. The 
remaining issues included the great lot-to-lot variation 
with each of the available tests, which makes compara-
bility from site to site or year to year very difficult. This 
issue is being improved by the manufacturers. A new 
rapid antibody-detection test for S. Paratyphi A-associa-
ted infection was presented. Even if these rapid tests can 
still be improved, they remain an alternative tool for the 
diagnosis of typhoid fever in the field.
Antimicrobial resistance in typhoid fever
Antibiotic resistance remains an important problem in 
Asia and in Africa because of the possibility to buy an-
tibiotics across the counter in the open market. Suscep-
tibility patterns of S. Typhi strains showed high rates of 
multidrug resistance (MDR) in Asia and in Africa, with 
rates of 40% of isolates from India, 70% from Pakistan, 
40% from Bangladesh, and 77% from Viet Nam. It was 
reported that more than 80% of isolates in Nigeria and 
60% in Cameroon had resistance against ciprofloxacin 
and ceftriaxone. A three-year study in Iran showed a fre-
quency of MDR of 50%, 67%, and 33% respectively 
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fluoroquinolone-resistant S. Paratyphi A was reported 
from India. In addition, resistance of S. Typhi to nali-
dix acid varied between none in Laos to low levels in 
isolates from China (5%), higher rates on the India sub-
continent (38%–Pakistan, 40%–Bangladesh, 61%–In-
dia), and higher levels in Viet Nam. Resistance of S. 
Paratyphi A to nalidixic acid was also reported in South 
China. Usually, the resistance to nalidixic acid is con-
sidered a marker for reduced susceptibility to fluoroqui-
nolones. It is still not known if the NaR in S. Paratyphi 
A has a clinical profile similar to resistance of S. Typhi 
to nalidixic acid. 
General Discussion
Clinical presentations, including cardiopulmonary 
manifestations, ileal perforation, carditis, and hepati-
tis in relation to typhoid fever cases, were discussed. 
Socio-behavioural research outlined the importance 
of studies on the acceptability of vaccine and uptake 
for the management of vaccine campaigns during a 
trial and for interpretation of disease patterns during 
vaccine-efficacy evaluation. 
  During discussion in the final session, the issue of 
the target age for vaccination to prevent typhoid fever 
was raised. Based upon the epidemiological data, the op-
timal window to immunize would be from 2 to 20 years 
of age. Some studies showed that infants aged less than 
two years could be infected by S. Typhi, although they 
did not develop a real clinical typhoid fever. Moreover, 
neither vaccine is recommended as effective in infants 
aged less than two years, although the Ty21a vaccine was 
not evaluated in this age range. The Vi conjugate vaccine 
is expected to be immunogenic in such infants. Finally, 
reference was made to the recommendation of WHO 
on vaccination which should be conducted in large-
scale nursery-based and school-based immunization 
programmes wherever the control of the disease is 
a priority with multidrug resistance strains of S. Typhi 
(2,3). 
  In conclusion, there was a consensus to recognize 
that infection caused by S. Typhi still remains an im-
portant public-health problem, particularly in Asia and 
probably in Africa. The need was expressed to arrange 
a meeting to re-visit the currently-available data on the 
estimates of morbidity and mortality due to typhoid fe-
ver. There was a concern about the worldwide spread of 
multi-drug resistance strains and the increasing emer-
gence in China and Pakistan of S. Paratyphi A isolates. 
Finally, it was noted that, despite the fact that typhoid fe-
ver vaccines are shown to be effective, either in prevent-
ing or during an outbreak of typhoid fever, there is still 
some reluctance towards vaccination as a public-health 
intervention, probably due to lack of information. The 
future uptake and recommendation of the implementa-
tion of typhoid fever vaccines needs to be addressed by 
the international community and should be the topic of 
a future meeting by WHO.
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